Events

NTNU European Conference 2025 - European R&I for Enhanced Competitiveness
SEP
Wed
24
08:30 - 15:00

Starts in 2 weeks from now

Location

Brussels and Online

Programmes
Culture and society Security Agro-Food, Environment

The 9th edition of the NTNU European Conference focuses on the following thematic areas: Civil security, Communities, and Ocean & Coast.

This event aims to explore how the evolution of guidelines and priorities set out by the commission, together with the potential of technology as a facilitating tool, can shape the future of European civil society and competitiveness on the global stage.

Topics covered in this conference:

  • The blossoming European Political and Strategic Landscape: challenges, complementarities and the role of R&I in a reinforced Approach to Competitiveness.
  • Securing Europe’s Blue Future: Leveraging Data for a Secure and Resilient Blue Europe
  • Beyond Democratic Resilience in a Digital Society: Challenges and Opportunities
  • The new R&I funding framework: an appropriate tool for approaching EU future challenges?

For more information and to register, please access the dedicated event page via this link.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.